rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    VERA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Vera Therapeutics stock hits 52-week low at 26.32 USD
      Nov 17Investing.comVERA
      Vera Therapeutics at Guggenheim conference: launch gains momentum
      Nov 10Investing.comVERA
      Vera Therapeutics Inc (VERA) (Q3 2026) Earnings Call Highlights: TRUTAKNA Launch Off to a ...

      Vera Therapeutics Inc (VERA) reported its first partial quarter of TRUTAKNA sales at $10.3 million and roughly 700 patient start forms, while advancing a supplemental BLA for full approval.

      Nov 7Yahoo FinanceVERA
      Vera Therapeutics Q3 Earnings Call Highlights
      Nov 6Yahoo FinanceVERA
      Vera Therapeutics (VERA) Stock Looks Above Fair Value After A 148% Run

      Vera Therapeutics has delivered a very strong 148.3% share price gain over the past 3 years, yet the recent pullback and mixed shorter term moves put fresh attention on what investors are actually paying for on its balance sheet. With that kind of run in the rear-view mirror and new product news in play, the open question is how today’s valuation lines up with the stock’s book value relative to the wider biotech industry. The 148.3% return over 3 years means anyone looking at Vera...

      Nov 6Yahoo FinanceVERA
      Guggenheim lowers Vera Therapeutics stock price target on model changes
      Nov 6Investing.comVERA
      Raymond James raises Vera Therapeutics price target on strong launch
      Nov 6Investing.comVERA
      Wedbush lowers Vera Therapeutics stock price target on competition
      Nov 6Investing.comVERA
      Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Nov 6Yahoo FinanceVERA
      Vera Therapeutics, Inc. Q3 2026 Earnings Call Summary
      Nov 6Yahoo FinanceVERA
      Vera Therapeutics earnings beat by $0.31, revenue topped estimates
      Nov 5Investing.comVERA
      Vera Therapeutics, Inc. (VERA) Reports Q3 Loss, Tops Revenue Estimates
      Nov 5Yahoo FinanceVERA
      Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

      TRUTAKNA® (atacicept-vymj) U.S. launch building early momentum following July 7 accelerated approval by the U.S. Food and Drug Administration (FDA) with approximately 700 Patient Start Forms (PSFs) to date and $10.3 million of net product revenue in Q3.ORIGIN 3 final efficacy analysis demonstrated stabilization of kidney function and a 76% reduction in risk of composite kidney disease progression versus placebo through two years; data was presented as a late-breaking oral presentation at the ope

      Nov 5Yahoo FinanceVERA
      Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
      Nov 2Yahoo FinanceVERA
      Raymond James reiterates Vera Therapeutics stock Strong Buy on kidney disease data
      Oct 26Investing.comVERARJF
      Cantor Fitzgerald reiterates Vera Therapeutics stock rating on kidney drug data
      Oct 23Investing.comVERA
      Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results
      Oct 23Yahoo FinanceVERA
      Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of...

      TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGF...

      Oct 22Business InsiderVERA
      Vera Therapeutics plans FDA filing for IgAN drug in Q4 2026
      Oct 22Investing.comVERA
      Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine
      Oct 22MorningstarVERA
      Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
      Oct 20Yahoo FinanceVERA
      Leerink Partners Initiates Vera Therapeutics at Market Perform With $34 Price Target
      Oct 12Yahoo FinanceVERA
      BofA Securities Adjusts Vera Therapeutics Price Target to $60 From $66, Maintains Buy Rating
      Oct 9Yahoo FinanceVERA
      Do Vera Therapeutics' (VERA) High-Profile IgAN Data Show Durable Moat or Crowded Mechanism Risk?
      Oct 8Yahoo FinanceVERA
      Vera Therapeutics to present IgA nephropathy trial data at ASN
      Oct 2Investing.comVERA
      Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

      BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, from October 22 to 25. The final efficacy analysis of the ORIGIN 3 trial of TRUTAKNA in IgA nephropathy (IgAN) will be a featured late-breaking oral presentation during the opening plenary session and also a late-breaking rese

      Oct 2Yahoo FinanceVERA
      Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Oct 2Yahoo FinanceVERA
      Vera Therapeutics (VERA) Says TRUTAKNA Met All Phase III Endpoints

      Vera Therapeutics (NasdaqGM: VERA) reported that TRUTAKNA met all prespecified endpoints in the final Phase III ORIGIN 3 trial for IgA nephropathy. The company said the study showed prevention of disease progression and stabilization of kidney function alongside a favorable safety profile. Management plans to seek full FDA approval for TRUTAKNA later in 2026 through a supplemental biologics license application. The confirmation of TRUTAKNA's Phase III success sits against a wider backdrop of...

      Sep 17Yahoo FinanceVERA
      Biotech Reverses Its Major Chart Upset — What Happened?

      Vera stock reversed course Tuesday despite positive results for its kidney disease treatment, a rival to drugs from Otsuka and Vertex.

      Sep 15Investor's Business DailyVERA
      Vera Therapeutics: Why I'm Sticking With 'Hold' Despite Positive Trutakna Data (VERA)

      Vera Therapeutics, Inc. gets FDA accelerated approval for Trutakna in IgA nephropathy, but competition and pricing risk remain. Click for this VERA update.

      Sep 15Seeking AlphaVERA
      What's Going on With Vera Therapeutics Stock on Tuesday?
      Sep 15BenzingaVERA
      Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results
      Sep 15Barron'sVERA
      TD Cowen reiterates Buy on Vera Therapeutics stock on kidney data
      Sep 15Investing.comVERA
      Vera Therapeutics stock maintained at Strong Buy by Raymond James
      Sep 15Investing.comVERARJF
      Vera Therapeutics Shares Rise 13% After TRUTAKNA Meets ORIGIN 3 Trial Endpoints

      Vera Therapeutics (NASDAQ:VERA) shares rose 13% on Tuesday after the company reported that TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis of its ORIGIN 3 trial in adults with primary IgA nephropathy. The company said the results showed that TRUTAKNA stabilised estimated glomerular filtration rate, or eGFR, and reduced kidney disease progression through two years in patients considered at risk of disease progression.

      Sep 15Yahoo FinanceVERA
      VERA Stock Jumps 16% Premarket – Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4

      Vera Therapeutics stated that Trutakna's commercial launch generated more than 350 patient start forms in the first 10 weeks.

      Sep 15Yahoo FinanceVERA
      Why is Vera Therapeutics stock surging today?
      Sep 15Investing.comVERA
      12 Health Care Stocks Moving In Tuesday's Pre-Market Session
      Sep 15BenzingaBDRXVERA
      Vera Therapeutics stock jumps on positive trial results
      Sep 15Investing.comVERA
      Vera Therapeutics Kidney Disease Drug Meets Prespecified Endpoints in Origin 3 Trial
      Sep 15Yahoo FinanceVERA
      Vera gains on Trutakna late-stage trial win (VERA:NASDAQ)
      Sep 15Seeking AlphaVERA
      Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
      Sep 15Yahoo FinanceVERA
      Vera set up for full approval for Trutakna in IgAN with Phase III win

      Vera’s Trutakna was granted FDA accelerated approval in IgAN based on 36-week data.

      Sep 15Yahoo FinanceVERA
      Vera Therapeutics at Cantor Fitzgerald conference: launch gains traction
      Sep 10Investing.comVERA
      Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 61,500 shares of Class A common stock and restricted stock units (RSUs) underlying 30,750 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024

      Sep 4Yahoo FinanceVERA
      Vera Therapeutics to Participate at Upcoming Investor Conferences

      BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: Cantor Global Healthcare Conference 2026Format: Fireside Chat and 1x1 investor meetings Webcast: https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=395559

      Sep 1Yahoo FinanceVERA
      Vera Therapeutics options activity points to institutional bullish call spread on September strikes
      Aug 25Investing.comVERA

      This is the newest page. Registered accounts read further back.